WFRF:(Godina Christopher)
Sökning: WFRF:(Godina Christopher) > Potential interplay...
- 9 av 9
- Föregående post
- Nästa post
- Till träfflistan
- Lindgren, HampusLund University,Lunds universitet,Cancerepidemiologi & strål,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cancerepidemiology and radiation,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital (författare)
Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis : a prospective cohort study
- Artikel/kapitelEngelska
Nummerbeteckningar
- LIBRIS-ID:oai:lup.lub.lu.se:2c6b01a1-f0d1-46e7-900a-f40ddc2043e9
- https://lup.lub.lu.se/record/2c6b01a1-f0d1-46e7-900a-f40ddc2043e9URI
- https://doi.org/10.1007/s10552-023-01845-1DOI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- Purpose: Vitamin D has some anticancer properties that may decrease breast cancer risk and improve prognosis. The aim was to investigate associations between four previously studied VDR SNPs (Taq1, Tru91, Bsm1, and Fok1) and prognosis in different groups of breast cancer patients. Methods: VDR genotyping of 1,017 breast cancer patients included 2002–2012 in Lund, Sweden, was performed using Oncoarray. Follow-up was until June 30, 2019. Clinical data and patient information were collected from medical records and questionnaires. Cox regression was used for survival analyses. Results: Genotype frequencies were as follows: Fok1 (AA 15.7%, AG 49.1%, GG 35.1%), Bsm1 (CC 37.2%, CT 46.1%, TT 16.7%), Tru91 (CC 77.8%, CT 20.7%, TT 1.5%), and Taq1 (AA 37.2%, AG 46.2%, GG 16.6%). During follow-up there were 195 breast cancer events. The homozygous variants of Taq1 and Bsm1 were associated with reduced risk of breast cancer events (adjusted HR = 0.59, 95% CI 0.38–0.92 for Taq1 and adjusted HR = 0.61, 95% CI 0.40–0.94 for Bsm1). The G allele of the Fok1 was associated with increased risk of breast cancer events in small tumors (pT1, adjusted HR = 1.83, 95% CI 1.04–3.23) but not in large tumors (pT2/3/4, adjusted HR = 0.80, 95% CI 0.41–1.59) with a borderline interaction (Pinteraction = 0.058). No interactions between VDR genotypes and adjuvant treatments regarding breast cancer prognosis were detected. Conclusion: VDR genotypes were associated with breast cancer prognosis and the association might be modified by tumor size. Further research is needed to confirm the findings and elucidate their potential clinical implications.
Ämnesord och genrebeteckningar
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
- Breast cancer
- Population-based cohort
- Prognosis
- Vitamin D receptor (VDR) polymoprhisms
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Ademi, DavidLund University,Lunds universitet,Cancerepidemiologi & strål,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cancerepidemiology and radiation,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)da0054ad (författare)
- Godina, ChristopherLund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Cancerepidemiologi & strål,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Cancerepidemiology and radiation,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)ch3385go (författare)
- Tryggvadottir, HelgaLund University,Lunds universitet,Epidemiologi och farmakogenetik,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Epidemiology and pharmacogenetics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)med-htg (författare)
- Isaksson, KarolinLund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lund Melanoma Study Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Central Hospital Kristianstad(Swepub:lu)kir-kis (författare)
- Jernström, HelenaLund University,Lunds universitet,Epidemiologi och farmakogenetik,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Cancerepidemiologi & strål,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Epidemiology and pharmacogenetics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Cancerepidemiology and radiation,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-hje (författare)
- Cancerepidemiologi & strålSektion I (creator_code:org_t)
Sammanhörande titlar
- Ingår i:Cancer Causes and Control0957-5243
Internetlänk
Hitta via bibliotek
- Cancer Causes and Control (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 9 av 9
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Lindgren, Hampus
- Ademi, David
- Godina, Christop ...
- Tryggvadottir, H ...
- Isaksson, Karoli ...
- Jernström, Helen ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Cancer Causes an ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
